For older liver patients, a familiar diabetes drug class is linked to fewer hospital stays

Among older adults with fatty liver disease, those treated with GLP-1 medicines — a class widely used for diabetes and weight — had lower risks of hospitalisation and death in a large Houston Methodist-led study published in Age and Ageing. The authors are careful: this kind of study shows links, not proof, and trials should confirm who benefits most. Still, for a condition that is now the leading cause of chronic liver disease in older adults, it is a promising lead.